Comparison of 2-Week Versus 4-Week Dosing Intervals of Epoetin Beta Pegol on Erythropoiesis and Iron Metabolism in Hemodialysis Patients

Therapeutic Apheresis and Dialysis

Volumn 18, Issue 5, 2014, Pages 414-420

  Morikami, Yuki ^a   Fujimori, Akira ^a   Okada, Shioko ^a   Kumei, Mai ^a   Mizobuchi, Noriko ^a   Sakai, Makoto ^a  

^a Konan Hospital   (Japan)

Author keywords

Dialysis; Epoetin beta pegol; Ferritin; Hepcidin 25; Renal anemia

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; HEPCIDIN 25, HUMAN; MACROGOL DERIVATIVE;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DOSAGE SCHEDULE COMPARISON; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON METABOLISM; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETICULOCYTE COUNT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RETICULOCYTE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMOGLOBINS; HEPCIDINS; HUMANS; IRON; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RENAL DIALYSIS; RETICULOCYTES;

EID: 84909977950     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12164     Document Type: Article

References (20)

1. Eschbach JW, Adamson JW. Recombinant human erythropoietin: implications for nephrology. Am J Kidney Dis 1988;11:203-209.
2. Shoji S, Inaba M, Tomosugi N etal. Greater potency of darbepoetin-alpha than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients. Eur J Haematol 2013;90:237-244.
3. Hayashi T, Kobayashi T, Kukita K etal. Pharmacokinetics of C.E.R.A. (Continuous Erythropoietin receptor Activator) in Japanese Chronic Kidney Disease Patients on Dialysis. Jpn Pharmacol Ther 2010;38:1175-1190.
4. Weinreich T, Leistikow F, Hartmann HG, Vollgraf G, Dellanna F. Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients. Hemodial Int 2012;16:11-19.
5. Gonzalez MT, Ramos R, Vera M etal. Monthly CERA treatment maintains stable hemoglobin levels in routine clinical practice of peritoneal dialysis patients. Ren Fail 2013;35:314-319.
6. Canaud B, Mingardi G, Braun J etal. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008;23:3654-3661.
7. Spinowitz B, Coyne DW, Lok CE etal. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol 2008;28:280-289.
8. Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom 2007;21:4033-4038.
9. Levin NW, Fishbane S, Canedo FV etal. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007;370:1415-1421.
10. Sulowicz W, Locatelli F, Ryckelynck JP etal. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007;2:637-646.
11. Hsu PY, Lin CL, Yu CC etal. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study. J Nephrol 2004;17:693-700.
12. Hasuike Y, Nonoguchi H, Tokuyama M etal. Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study. Clin Exp Nephrol 2010;14:349-355.
13. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001;60:2406-2411.
14. Pigeon C, Ilyin G, Courselaud B etal. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276:7811-7819.
15. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010;55:726-741.
16. Nemeth E, Tuttle MS, Powelson J etal. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
17. Kuragano T, Shimonaka Y, Kida A etal. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol 2010;31:534-540.
18. Dallalio G, Law E, Means RT Jr. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 2006;107:2702-2704.
19. Sasaki Y, Noguchi-Sasaki M, Yasuno H, Yorozu K, Shimonaka Y. Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice. Int J Hematol 2012;96:692-700.
20. Kuragano T, Itoh K, Shimonaka Y etal. Hepcidin as well as TNF-alpha are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant 2011;26:2663-2667.